Comparison of Insulin glargine 300 U/ml + SGLT2 inhibitor therapy (Tofogliflozin 20 mg vs. Ipragliflozin 50 mg) using continuous glucose monitoring (CGM): randomised crossover study

Trial Profile

Comparison of Insulin glargine 300 U/ml + SGLT2 inhibitor therapy (Tofogliflozin 20 mg vs. Ipragliflozin 50 mg) using continuous glucose monitoring (CGM): randomised crossover study

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Tofogliflozin (Primary) ; Insulin glargine; Ipragliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2017 Status changed from recruiting to completed.
    • 24 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top